6 assets in Mycosis Fungoides And Variants

Therapeutic assets addressing Mycosis Fungoides And Variants, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pembrolizumab Mycosis Fungoides And Variants	University of Michigan Rogel Cancer Center	P2	BB (64)
Mogamulizumab Mycosis Fungoides And Variants	University of Michigan Rogel Cancer Center	P2	B (60)
Duvelisib Mycosis Fungoides And Variants	National Cancer Institute (NCI)	P1	CC (43)
Nivolumab Mycosis Fungoides And Variants	National Cancer Institute (NCI)	P1	CC (43)
Tulmimetostat Mycosis Fungoides And Variants	Washington University School of Medicine	P1	CC (43)